viimane versioon :
19/11/2024
mitmesugune   Ursodesoxycholique acid  
suukaudne lahus
Stabiilsust ravimpreparaadid Stabiilsust mõjutavad tegurid stabiilsust mõjutavad faktorid Sobimatus Viited pdf
   keemiline struktuur  

suukaudne lahus
Viited   suukaudne lahus   Viited : Ursodesoxycholique acid  
tüüp avaldamine
2410 ajaleht Johnson CE, Streetman DD.
Stability of oral suspensions of ursodiol made from tablets
Am J Health-Syst Pharm 2002 ; 59: 361-363.
2449 ajaleht Johnson CE, Nesbitt J.
Stability of ursodiol in an extemporaneously compounded oral liquid
Am J Health-Syst Pharm 1995 ; 52: 1798-1800.
3782 ajaleht A. Santove?a, E. S?nchez-Negr?n, L. Charola, M. Llabr?s, J.B. Fari?a
­Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration
Int J Pharm 2014 , 477, 1-2 : 32-38.
4177 ajaleht Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4214 ajaleht Pramar Y.V, Mandal T.K, Bostanian L.A, Nguyen A.TQ, Miller V, Morris T.C, Graves R.A.
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
Int J Pharm Compound 2019 ;23,1:70-76
4498 ajaleht Hausherr A, Roessle C, Pinet E, Vasseur V, Abarou T, Benakouche S, Bourdon O, Storme T.
Development and validation of a new HPLC method for the analysis of a novel oral suspension formulation of 50 mg/mL ursodesoxycholic acid for newborns.
Pharmaceutical Technology in Hospital Pharmacy 2020

  Mentions Légales